SFZN Stock Overview
Provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 1,052.00 |
| 52 Week High | CHF 1,188.00 |
| 52 Week Low | CHF 831.50 |
| Beta | 0.71 |
| 1 Month Change | 6.48% |
| 3 Month Change | -7.39% |
| 1 Year Change | 18.20% |
| 3 Year Change | 49.11% |
| 5 Year Change | 120.08% |
| Change since IPO | 1,284.21% |
Recent News & Updates
Siegfried Holding AG's (VTX:SFZN) Price In Tune With Earnings
Nov 09
Is Siegfried Holding (VTX:SFZN) Using Too Much Debt?
Sep 12Recent updates
Siegfried Holding AG's (VTX:SFZN) Price In Tune With Earnings
Nov 09Is Siegfried Holding (VTX:SFZN) Using Too Much Debt?
Sep 12A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Aug 04Siegfried Holding AG (VTX:SFZN) Not Flying Under The Radar
Jun 17Siegfried Holding AG's (VTX:SFZN) CEO Compensation Looks Acceptable To Us And Here's Why
Apr 12Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Mar 15Earnings Miss: Siegfried Holding AG Missed EPS By 18% And Analysts Are Revising Their Forecasts
Feb 23Shareholder Returns
| SFZN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 2.5% | 0.3% | 0.9% |
| 1Y | 18.2% | 21.2% | 10.4% |
Return vs Industry: SFZN underperformed the Swiss Life Sciences industry which returned 21.2% over the past year.
Return vs Market: SFZN exceeded the Swiss Market which returned 10.4% over the past year.
Price Volatility
| SFZN volatility | |
|---|---|
| SFZN Average Weekly Movement | 3.6% |
| Life Sciences Industry Average Movement | 4.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 8.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: SFZN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: SFZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,797 | Marcel Imwinkelried | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products.
Siegfried Holding AG Fundamentals Summary
| SFZN fundamental statistics | |
|---|---|
| Market cap | CHF 4.51b |
| Earnings (TTM) | CHF 128.86m |
| Revenue (TTM) | CHF 1.28b |
35.0x
P/E Ratio3.5x
P/S RatioIs SFZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFZN income statement (TTM) | |
|---|---|
| Revenue | CHF 1.28b |
| Cost of Revenue | CHF 952.10m |
| Gross Profit | CHF 332.25m |
| Other Expenses | CHF 203.38m |
| Earnings | CHF 128.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | 30.04 |
| Gross Margin | 25.87% |
| Net Profit Margin | 10.03% |
| Debt/Equity Ratio | 47.4% |
How did SFZN perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/11 01:48 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Siegfried Holding AG is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Laura Lopez Pineda | Baader Helvea Equity Research |